All In Biotech

Drug Trial Radar · NCT06809179

A Clinical Trial to Assess the Efficacy, Safety, and Tolerability of a Repeat Dose of Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder

A Phase 2, Three-arm, Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial to Assess the Efficacy, Safety, and Tolerability of a Repeat Dose of Fasedienol (PH94B) Nasal Spray for the Acute Treatment of Anxiety Induced by a Public Speaking Challenge in Adult Subjects With Social Anxiety Disorder, With an Open-Label Extension

Last checked: Nov 19, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

61

Actual

Start

Jan 9, 2025

Primary completion

Jun 12, 2026

Study completion Aug 26, 2026

Sponsor

Lead sponsor
VistaGen Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Feb 5, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This U.S. multicenter, double-blind, placebo-controlled Phase 2 clinical trial is designed to evaluate the efficacy, safety, and tolerability of a repeat intranasal (i.n.) dose of Fasedienol Nasal Spray (fasedienol) (3.2 µg) to relieve symptoms of acute anxiety in adult subjects ages 18 through 65 with Social Anxiety Disorder induced by a public speaking challenge (PSC) in a clinical setting. In addition, safety and tolerability of i.n. administration of 3.2 µg of fasedienol, as-needed, up to 6 times per day for up to 12 months, will be assessed in those subjects who complete PH94B-CL036 and choose to enter the distinct open-label extension phase of the study.

Conditions

  • Social Anxiety Disorder

Interventions

  • Fasedienol Nasal Spray - Placebo Nasal SprayDrug

    Twenty minutes prior to the PSC, subjects will receive one dose of Fasedienol Nasal Spray followed by one dose of Placebo Nasal Spray, separated by 10-minutes in between the two doses.

  • Fasedienol Nasal Spray - Fasedienol Nasal SprayDrug

    Twenty minutes prior to the PSC, subjects will receive one dose of Fasedienol Nasal Spray followed by a second dose of Fasedienol Nasal Spray, separated by 10-minutes in between the two doses.

  • Placebo Nasal Spray - Placebo Nasal SprayDrug

    Twenty minutes prior to the PSC, subjects will receive one dose of Placebo Nasal Spray followed by a second dose of Placebo Nasal Spray, separated by 10-minutes between the two doses.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Subjective Units of Distress Scale (SUDS)Time frame: 7 days (Visit 2 to Visit 3)

Locations

9 sites in 1 country. Site status is shown where the registry gives one.

  • Vistagen Clinical Site

    Sherman Oaks, California

  • Vistagen Clinical Site

    Walnut Creek, California

  • Vistagen Clinical Site

    Largo, Florida

  • Vistagen Clinical Site

    Saint Charles, Missouri

  • Vistagen Clinical Site

    Toms River, New Jersey

  • Vistagen Clinical Site

    Cary, North Carolina

  • Vistagen Clinical Site

    Cleveland, Ohio

  • Vistagen Clinical Site

    Plymouth Meeting, Pennsylvania

  • Vistagen Clinical Site

    Plano, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.